Cytokine-induced killer cells in the treatment of patients with solid carcinomas: a systematic review and pooled analysis

References

• Schmidt-Wolf IG, Negrin RS, Kiem HP, Blume KG, Weissman IL. . Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med. 1991;174:139–49.
   PubMed Web of Science ®Google Scholar
• Dillman RO, Duma CM, Ellis RA, Cornforth AN, Schiltz PM, Sharp SL, . Intralesional lymphokine-activated killer cells as adjuvant therapy for primary glioblastoma. J Immunother. 2009;32:914–19.
   PubMed Web of Science ®Google Scholar
• Schmidt-Wolf IG, Lefterova P, Metha BA, Fernandez LP, Huhn D, Blume KG, . Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells. J. Exp Hematol. 1993;21:1673–9.
   PubMed Web of Science ®Google Scholar
• Joshi PS, Liu JQ, Wang Y, Chang X, Richards J, Assarsson E, . Cytokine-induced killer T cells kill immature dendritic cells by TCR-independent and perforin-dependent mechanisms. J Leukoc Biol. 2006;80:1345–53.
   PubMed Web of Science ®Google Scholar
• Linn YC, Hui KM. Cytokine-induced NK-like T cells: from bench to bedside. J Biomed Biotechnol. 2010:1–8.
   Google Scholar
• Hontscha C, Borck Y, Zhou H, Messmer D, Schmidt-Wolf IG. Clinical trials on CIK cells: first report of the international registry on CIK cells (IRCC). J Cancer Res Clin Oncol. 2010;137:305–10.
   Google Scholar
• Bonanno G, Iudicone P, Mariotti A, Procoli A, Pandolfi A, Fioravanti D, . Thymoglobulin, interferon-γ and interleukin-2 efficiently expand cytokine-induced killer (CIK) cells in clinical-grade cultures. J Transl Med. 2010;7:129–143.
   Google Scholar
• Introna M, Pievani A, Borleri G, Capelli C, Algarotti A, Micó C, . Feasibility and safety of adoptive immunotherapy with CIK cells after cord blood transplantation. Biol Blood Marrow Transplant. 2010;16:1603–7.
   PubMed Web of Science ®Google Scholar
• Schmidt-Wolf IG, Finke S, Trojaneck B, Denkena A, Lefterova P, Schwella N, . Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma. Br J Cancer. 1999;81:1009–16.
   PubMed Web of Science ®Google Scholar
• Yates JW, Chalmer B, McKegney FP. Evaluation of patients with advanced cancer using the Karnofsky performance status. Cancer. 1980;45:2220–24.
   PubMed Web of Science ®Google Scholar
• Hollen PJ, Gralla RJ, Kris MG, Cox C. Quality of life during clinical trials: conceptual model for the Lung Cancer Symptom Scale (LCSS). Support Care Cancer. 1994;2:2213–22.
   Google Scholar
• Rosenthal R. The file drawer problem and tolerance for null results. Psychol Bull. 1979;86:638–41.
   Web of Science ®Google Scholar
• Thornton A, Lee P. Publication bias in meta-analysis: its causes and consequences. J Clin Epidemiol. 2000;53: 207–16.
   PubMed Web of Science ®Google Scholar
• Sutton JA, Song F, Gilbody MS, Abrams KR. Modelling publication bias in meta-analysis: a review. Stat Meth Med Res. 2000;9:421–45.
   PubMed Web of Science ®Google Scholar
• Hao MZ, Lin HL, Chen Q, Ye YB, Chen QZ, Chen MS. Efficacy of transcatheter arterial chemoembolization combined with cytokine-induced killer cell therapy on hepatocellular carcinoma: a comparative study. Chin J Cancer. 2010:29:172–77.
   PubMedGoogle Scholar
• Pan CC, Huang ZL, Li W, Zhao M, Zhou QM, Xia JC, . Serum alpha-fetoprotein measurement in predicting clinical outcome related to autologous cytokine-induced killer cells in patients with hepatocellular carcinoma undergoing minimally invasive therapy. Chin J Cancer. 2010:29:596–602.
   Google Scholar
• Pugh RN, Murray-Lyon IM, Dawson JL, . Transection of the oesophagus for bleeding oesophageal varices. The British journal of surgery. 1973; 60:646–49.
   PubMed Web of Science ®Google Scholar
• Zhao M, Wu PH, Zeng YX, Xia JC, Zhang FJ, Xian LJ, . Cytokine-induced killer cell fusion to lower recurrence of hepatocellular carcinoma after transcatheter arterial chemoembolization sequentially combined with radiofrequency ablation: a randomized trial. Zhonghua Yi Xue Za Zhi. 2006;86:1823–28.
   PubMedGoogle Scholar
• Weng DS, Zhou J, Zhou QM, Zhao M, Wang QJ, Huang LX, . Minimally invasive treatment combined with cytokine-induced killer cells therapy lower the short-term recurrence rates of hepatocellular carcinomas. J Immunother. 2008;31:63–71.
   PubMed Web of Science ®Google Scholar
• Hui D, Qiang L, Jian W, Ti Z, Da-Lu K. A randomized, controlled trial of postoperative adjuvant cytokine-induced killer cells immunotherapy after radical resection of hepatocellular carcinoma. J Dig Liver Dis. 2009;41:36–41.
   PubMedGoogle Scholar
• Introna M, Borleri G, Conti E, Franceschetti M, Barbui AM, Broady R, . Repeated infusions of donor-derived cytokine-induced killer cells in patients relapsing after allogeneic stem cell transplantation: a phase I study. Haematologica. 2007;92: 952–9.
   PubMed Web of Science ®Google Scholar
• Li Q, Chang AE. Adoptive T-cell immunotherapy of cancer. Cytokines Cell Mol Ther 1999; 5:105-17.
   Google Scholar
• Wang H, Zhou FJ, Wang QJ, Qin ZK, Huang LX, Liu ZW . Efficacy of autologous renal tumor cell lysate-loaded dendritic cell vaccine in combination with cytokine-induced killer cells on advanced renal cell carcinoma: a report of ten cases. Ai Zheng. 2006;25:625–30.
   PubMedGoogle Scholar
• Jiang H, Liu KY, Tong CR, Jiang B, Lu DP. The efficacy of chemotherapy in combination with auto-cytokine-induced killer cells in acute leukemia. Zhonghua Nei Ke Za Zhi. 2005;44:198–201.
   Google Scholar
• Verneris MR, Karami M, Baker J, Jayaswal A, Negrin RS. Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells. Blood. 2004;103:3065–72.
   PubMed Web of Science ®Google Scholar
• Yu J, Zhang W, Jiang H, Li H, Cao S, Ren X. CD4+ T cells in CIKs (CD4+ CIKs) reversed resistance to fas-mediated apoptosis through CD40/CD40L ligation rather than IFN-gamma stimulation. Cancer Biother Radiopharm. 2008;23:342–54.
   Google Scholar
• Li SY, Zhang CJ, Wang SY, Wu QI, Zhao SQ, Pei CY. Study of inhibitory effects of CIK on Lewis lung carcinoma. Zhong Guo Xian Dai Yi Xue Za Zhi. 2007;21:2605–8.
   Google Scholar
• Schmidt-Wolf GD, Negrin RS, Schmidt-Wolf IG. Activated T cells and cytokine-induced CD3+ CD56+ killer cells. Ann Hematol. 1997;74:51–6.
   PubMed Web of Science ®Google Scholar
• Michielsen P, Ho E. Viral hepatitis B and hepatocellular carcinoma. J. Acta Gastroenterol Belg. 2011;74:4–8.
   PubMed Web of Science ®Google Scholar
• Kastelan Z, Lukac J, Derezic D, Pasini J, Kusić Z, Sosić H, . Lymphocyte subsets, lymphocyte reactivity to mitogens, NK cell activity and neutrophil and monocyte phagocytic functions in patients with bladder carcinoma. Anticancer Res. 2003;23:5185–89.
   PubMed Web of Science ®Google Scholar
• Ladhams A, Schmidt C, Sing G, Butterworth L, Fielding G, Tesar P, . Treatment of non-resectable hepatocellular carcinoma with autologous tumor-pulsed dendritic cells. J Gastroenterol Hepatol. 2002;17:889–96.
   PubMed Web of Science ®Google Scholar
• Lu W, Li YH, He XF, Chen Y, Zeng QL, Qiu YR. Effect of dosage of anticancer agents during transcatheter arterial chemoembolization on T cell subsets in patients with hepatocellular carcinoma. J Di Yi Jun Yi Da Xue Xue Bao. 2002; 22:524–26.
   PubMedGoogle Scholar
• Zhang YS, Yuan FJ, Jia GF, Zhang JF, Hu LY, Huang L, . CIK cells from patients with HCC possess strong cytotoxicity to multidrug resistant cell line. J World J Gastroenterol. 2005;11:3339–45.
   PubMed Web of Science ®Google Scholar
• Märten A, Ziske C, Schöttker B, Renoth S, Weineck S, Buttgereit P, . Interactions between dendritic cells and cytokine-induced killer cells lead to an activation of both populations. J Immunother. 2001;24:502–10.
   PubMed Web of Science ®Google Scholar
• Joshi PS, Lir JQ, Wang Y, Chang X, Richards J, Assarsson E, . Cytokine-induced killer T cells kill immature dendritic cells by Tcr-independent and perforin-dependent mechanisms. J Leukoc Biol. 2006;80:1345–53.
   PubMed Web of Science ®Google Scholar
• Saikh KU, Dyas B, Kissner T, Ulrich RG. CD56+ T-cell responses to bacterial superantigens and immune recognition of attenuated vaccines. Clin Diagn Lab Immunol. 2003; 10:1065–73.
   Google Scholar
• Cao JP, Jiang ZM, Zhang XC, Lin D, Chen W, Sun YH, . The proliferation, phenotype change and anti-tumor activity of cytokine induced killer cell. J Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2005;21:583–86.
   Google Scholar
• Kambe N, Kambe M, Chang HW, Matsui A, Min HK, Hussein M, . An improved proved procedure for the development of human mast cells from dispersed fetal liver cells in serum-free culture medium. J Immounol Methods. 2000;240:101–10.
   PubMed Web of Science ®Google Scholar
• Gluckman E, Rocha V. Cord blood transplantation: state of the art. Hematologica. 2009;94:451–4.
   PubMed Web of Science ®Google Scholar
• Li Y, Schmidt-Wolf IG, Wu YF, Huang SL, Wei J, Fang J, . Optimized protocols for generation of cord blood-derived cytokine-induced killer/natural killer cells. J Anticancer Res. 2010;30:3493–99.
   PubMed Web of Science ®Google Scholar
• Zhao G, Huang Y, Ye L, Duan L, Zhou Y, Yang K, . Therapeutic efficacy of traditional vein chemotherapy and bronchial arterial infusion combining with CIKs on III stage non-small cell lung cancer. Zhongguo Fei Ai Za Zhi. 2009; 12:1000–4.
   PubMedGoogle Scholar
• Wu C, Jiang J, Shi L, Xu N. Prospective study of chemotherapy in combination with cytokine-induced killer cells in patients suffering from advanced non-small cell lung cancer. Anticancer Res. 2008;28:3997–4002.
   PubMed Web of Science ®Google Scholar
• Jiang J, Wu C, Shi L, N Xu, H Deng, M Lu, . Side effects during treatment of advanced gastric carcinoma by chemotherapy combined with CIK-cell transfusion in elderly people. Clin Oncol Cancer Res. 2008;5:79–82.
   Google Scholar
• Jiang J, Xu N, Wu C, Deng H, Lu M, Li M, . Treatment of advanced gastric cancer by chemotherapy combined with autologous cytokine-induced killer cells. Anticancer Res. 2006;26:2237–42.
   PubMed Web of Science ®Google Scholar
• Lei K, Wng J, Jia Y, Xiong Y, Yuan Z. The effects of CIK cells on the treatment of renal cell carcinoma. Chinese-German J Clinical Oncol. 2009;8:346–48.
   Google Scholar
• Niu Q, Wang W, Li Y, Qin S, Wang Y, Wan G, . Cord blood-derived cytokine-induced killer cells biotherapy combined with second-line chemotherapy in the treatment of advanced solid malignancies. J Int Immunopharmacol. 2011;11:449–56.
   PubMed Web of Science ®Google Scholar